Literature DB >> 12053177

Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer.

Nisha Anand1, Sabita Murthy, Gudrun Amann, Meredith Wernick, Lisa A Porter, I Howard Cukier, Colin Collins, Joe W Gray, Joachim Diebold, Doug J Demetrick, Jonathan M Lee.   

Abstract

We have found that EEF1A2, the gene encoding protein elongation factor EEF1A2 (also known as eEF-1 alpha 2), is amplified in 25% of primary ovarian tumors and is highly expressed in approximately 30% of ovarian tumors and established cell lines. We have also demonstrated that EEF1A2 has oncogenic properties: it enhances focus formation, allows anchorage-independent growth and decreases the doubling time of rodent fibroblasts. In addition, EEF1A2 expression made NIH3T3 fibroblasts tumorigenic and increased the growth rate of ES-2 ovarian carcinoma cells xenografted in nude mice. Thus, EEF1A2 and the process of protein elongation are likely to be critical in the development of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12053177     DOI: 10.1038/ng904

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  79 in total

1.  eEF1A phosphorylation in the nucleus of insulin-stimulated C2C12 myoblasts: Ser⁵³ is a novel substrate for protein kinase C βI.

Authors:  Manuela Piazzi; Alberto Bavelloni; Irene Faenza; William Blalock; Andrea Urbani; Simona D'Aguanno; Roberta Fiume; Giulia Ramazzotti; Nadir Mario Maraldi; Lucio Cocco
Journal:  Mol Cell Proteomics       Date:  2010-10-05       Impact factor: 5.911

2.  Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy.

Authors:  Yibing Ruan; Anna Kovalchuk; Aarthi Jayanthan; Xueqing Lun; Yoji Nagashima; Olga Kovalchuk; James R Wright; Alfredo Pinto; Adam Kirton; Ronald Anderson; Aru Narendran
Journal:  Neuro Oncol       Date:  2014-11-12       Impact factor: 12.300

Review 3.  Not just for housekeeping: protein initiation and elongation factors in cell growth and tumorigenesis.

Authors:  Sarah Thornton; Nisha Anand; Dan Purcell; Jonathan Lee
Journal:  J Mol Med (Berl)       Date:  2003-08-01       Impact factor: 4.599

4.  Up-regulation of expression of translation factors--a novel molecular mechanism for cadmium carcinogenesis.

Authors:  Pius Joseph; Yi-Xiong Lei; Tong-man Ong
Journal:  Mol Cell Biochem       Date:  2004-01       Impact factor: 3.396

5.  Eukaryotic protein synthesis inhibitors identified by comparison of cytotoxicity profiles.

Authors:  Jenny Chan; Shakila N Khan; Isabelle Harvey; William Merrick; Jerry Pelletier
Journal:  RNA       Date:  2004-03       Impact factor: 4.942

6.  Defects in translational regulation mediated by the alpha subunit of eukaryotic initiation factor 2 inhibit antiviral activity and facilitate the malignant transformation of human fibroblasts.

Authors:  Darren J Perkins; Glen N Barber
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

7.  Purification, crystallization and preliminary X-ray crystallographic analysis of mammalian translation elongation factor eEF1A2.

Authors:  A Yaremchuk; V F Shalak; O V Novosylna; B S Negrutskii; T Crépin; A V El'skaya; M Tukalo
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-02-22

8.  Differential expression of ribosomal proteins in a human metastasis model identified by coupling 2-D liquid chromatography and mass spectrometry.

Authors:  Paweena Kreunin; Chul Yoo; Virginia Urquidi; David M Lubman; Steve Goodison
Journal:  Cancer Genomics Proteomics       Date:  2007 Sep-Oct       Impact factor: 4.069

9.  The eukaryotic translation elongation factor eEF1A2 induces neoplastic properties and mediates tumorigenic effects of ZNF217 in precursor cells of human ovarian carcinomas.

Authors:  Yu Sun; Nicholas Wong; Yinghui Guan; Clara M Salamanca; Jung Chien Cheng; Jonathan M Lee; Joe W Gray; Nelly Auersperg
Journal:  Int J Cancer       Date:  2008-10-15       Impact factor: 7.396

10.  Structural rationale for the cross-resistance of tumor cells bearing the A399V variant of elongation factor eEF1A1 to the structurally unrelated didemnin B, ternatin, nannocystin A and ansatrienin B.

Authors:  Pedro A Sánchez-Murcia; Álvaro Cortés-Cabrera; Federico Gago
Journal:  J Comput Aided Mol Des       Date:  2017-09-12       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.